Vertex Energy (VTNR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

NEW YORK, NY / ACCESSWIRE / February 16, 2016 / Vertex Pharmaceuticals Inc. (VRTX) was down by as much as 11.4% to $81.98 yesterday as investors were split on its earnings, reported after market close ...

Vertex Pharmaceuticals(NASDAQ: VRTX) has long been known for its expertise in treating cystic fibrosis (CF). The biotech is the market leader, bringing in billions of dollars in revenue and profit ...

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

- In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and superior in reducing sweat chloride compared to TRIKAFTA - - Approximately 3,800 people in Canada are now eligible for ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

In its upcoming report, Vertex Pharmaceuticals (VRTX) is predicted by Wall Street analysts to post quarterly earnings of $4.22 per share, reflecting a decline of 11.3% compared to the same period last ...

Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned ...